- Home
- AMS vs CLRB Comparison
AMS vs CLRB Comparison
Compare AMS & CLRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMS
- CLRB
- Stock Information
- Founded
- AMS 1980
- CLRB 2002
- Country
- AMS United States
- CLRB United States
- Employees
- AMS N/A
- CLRB N/A
- Industry
- AMS Medical Specialities
- CLRB Biotechnology: Pharmaceutical Preparations
- Sector
- AMS Health Care
- CLRB Health Care
- Exchange
- AMS Nasdaq
- CLRB Nasdaq
- Market Cap
- AMS 15.1M
- CLRB 12.8M
- IPO Year
- AMS N/A
- CLRB N/A
- Fundamental
- Price
- AMS $2.23
- CLRB $3.31
- Analyst Decision
- AMS
- CLRB Hold
- Analyst Count
- AMS 0
- CLRB 2
- Target Price
- AMS N/A
- CLRB N/A
- AVG Volume (30 Days)
- AMS 50.7K
- CLRB 343.2K
- Earning Date
- AMS 11-12-2025
- CLRB 11-17-2025
- Dividend Yield
- AMS N/A
- CLRB N/A
- EPS Growth
- AMS N/A
- CLRB N/A
- EPS
- AMS N/A
- CLRB N/A
- Revenue
- AMS $29,251,000.00
- CLRB N/A
- Revenue This Year
- AMS $5.06
- CLRB N/A
- Revenue Next Year
- AMS N/A
- CLRB N/A
- P/E Ratio
- AMS N/A
- CLRB N/A
- Revenue Growth
- AMS 26.61
- CLRB N/A
- 52 Week Low
- AMS $2.20
- CLRB $3.31
- 52 Week High
- AMS $3.59
- CLRB $66.00
- Technical
- Relative Strength Index (RSI)
- AMS 40.83
- CLRB 28.66
- Support Level
- AMS $2.25
- CLRB $3.70
- Resistance Level
- AMS $2.38
- CLRB $4.10
- Average True Range (ATR)
- AMS 0.08
- CLRB 0.32
- MACD
- AMS -0.01
- CLRB -0.16
- Stochastic Oscillator
- AMS 10.71
- CLRB 3.30
About AMS American Shared Hospital Services
American Shared Hospital Services provides stereotactic radiosurgery equipment, Advanced radiation therapy, and related equipment. It currently provides Gamma Knife units to medical centers and stand-alone facilities. The company, along with its subsidiaries, operates through the following operations: Gamma Knife, Advanced Radiation Therapy Equipment and Services, and Proton Beam Radiation Therapy Operations. It generates most of its revenue from the domestic market.
About CLRB Cellectar Biosciences Inc.
Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage a proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. It has one operating and reportable segment focused on utilizing its PDC platform to develop drugs for the treatment of cancer.